MedTrace Logo

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

NCT00293488 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-06-23

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I trial is studying the side effects and best dose of SL-11047 in treating patients with relapsed or refractory lymphoma.

Conditions

Interventions

DRUG

polyamine analogue PG11047

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Progen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Barbara Hicks · Progen Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293488 on ClinicalTrials.gov